Pfizer shares tumbled more than 7 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid-19 products.
輝瑞(Pfizer)股價下跌逾7%，先前這家美國製藥商預計的2024年營收低於市場共識預期。該公司正試圖摸索出在沒有重磅新冠(Covid-19)產品的情況下實現未來成長的道路。
您已閱讀12%（305字），剩餘88%（2314字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。